Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 14, 2018 - Issue 4
Submit an article Journal homepage
381
Views
1
CrossRef citations to date
0
Altmetric
Drug Evaluation

Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma

Erin E. BurkeMoffitt Cancer Center, Tampa, FL, USAView further author information
&
Jonathan S. ZagerDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USACorrespondence[email protected]
View further author information
Pages 469-473 | Received 14 Nov 2017, Accepted 19 Mar 2018, Published online: 23 Mar 2018

References

  • SEER cancer stat facts: melanoma of the skin. Bethesda, MD [updated 2017 Apr; cited 2017 Oct 23]. Available from: http://seer.cancer.gov/statfacts/html.melan.html
  • Luke JJ, Flaherty KT, Ribas A, et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017 Aug;14(8):463–482. PubMed PMID: 28374786.
  • Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015 May 21;372(21):2006–2017. PubMed PMID: 25891304.
  • Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017 Nov 09;377(19):1824–1835. PubMed PMID: 28891423.
  • Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015 Jan 01;372(1):30–39. PubMed PMID: 25399551.
  • Saranga-Perry V, Ambe C, Zager JS, et al. Recent developments in the medical and surgical treatment of melanoma. CA Cancer J Clin. 2014 May-Jun;64(3):171–185. PubMed PMID: 24676837.
  • Sloot S, Rashid OM, Sarnaik AA, et al. Developments in intralesional therapy for metastatic melanoma. Cancer Control. 2016 Jan;23(1):12–20. PubMed PMID: 27009452; PubMed Central PMCID: PMCPMC4904721.
  • Andtbacka RH, Ross M, Puzanov I, et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann Surg Oncol. 2016 Dec;23(13):4169–4177. PubMed PMID: 27342831; PubMed Central PMCID: PMCPMC5090012.
  • Sloot S, Rashid OM, Zager JS. Intralesional therapy for metastatic melanoma. Expert Opin Pharmacother. 2014 Dec;15(18):2629–2639. PubMed PMID: 25381015.
  • Gangi A, Zager JS. The safety of talimogene laherparepvec for the treatment of advanced melanoma. Expert Opin Drug Saf. 2017 Feb;16(2):265–269. PubMed PMID: 27989216.
  • Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015 Sep 01;33(25):2780–2788. PubMed PMID: 26014293.
  • Doepker MP, Zager JS. An update on talimogene laherparepvec. Am J Hematol/Oncol. 2016 [cited 2017 Apr];12(4):17–20.
  • Amgen. Imlygic (talimogene laherperepvec) suspension for intralesional injection: US prescribing information. 2015 [cited 2017 Oct 17]. Available from: http://www.fda.gov
  • Kaufman HL, Ruby CE, Hughes T, et al. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer. 2014;2:11, PubMed PMID: 24971166; PubMed Central PMCID: PMCPMC4072479
  • Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006 Nov 15;12(22):6737–6747. PubMed PMID: 17121894.
  • Kaufman HL, Kim DW, DeRaffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010 Mar;17(3):718–730. PubMed PMID: 19915919.
  • Andtbacka RHI, Mehnert J, Nemunaitis J, et al. Biodistribution and shedding of talimogene laherparepvec (T-VEC) in patients (Pts) with unresectable stage IIIB/IV melanoma. 9th World Congress on Melanoma; Oct 18–21, 2017; Brisbane, Australia.
  • Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009 Dec 01;27(34):5763–5771. PubMed PMID: 19884534.
  • Kaufman HL, Bines SD. OPTIM trial: a phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol. 2010 Jun;6(6):941–949. PubMed PMID: 20528232.
  • Chesney J, Puzanov I, Collichio F, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 2017 Oct 05;JCO2017737379. PubMed PMID: 28981385.
  • Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017 Sep 07;170(6):1109–1119.e10. PubMed PMID: 28886381.
  • Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015 Jun 25;372(26):2521–2532. PubMed PMID: 25891173.
  • Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003 Feb;10(4):292–303. PubMed PMID: 12595888.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.